• Vaccine Name: Brucella melitensis lipopolysaccharide subunit vaccine with MONTANIDE ISA 61 VG adjuvant
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009599
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Goat
• Host Species as Laboratory Animal Model: Capra hircus; peripheral blood mononuclear cells (PBMC)
• Antigen: lipopolysaccharide (LPS)
• Adjuvant: MONTANIDE‚Ñ¢ ISA 61 VG
• Preparation: LPS from B. melitensis strain 16M formulated with MONTANIDE‚Ñ¢ ISA 61 VG adjuvant. (Naseer et al, 2025)
• Description: The study evaluated immunologic responses and protection against experimental challenge in goats vaccinated with LPS combined with ISA 61 VG adjuvant. Efficacy: Vaccination with LPS + ISA 61 VG did not confer protection against abortion, uterine, fetal, mammary, or maternal infection compared to controls. Immune response: LPS + ISA 61 VG induced significantly greater antibody responses and lymphocyte proliferative responses to LPS antigen than LPS alone; however, T cell proliferation and antigen-specific IFN-γ production were negligible and not different from controls. (Naseer et al, 2025)

Goat Response

• Host cell type: PBMC
• Immune Response: LPS + ISA 61 VG induced significantly greater antibody responses and lymphocyte proliferative responses to LPS antigen than LPS alone; however, T cell proliferation and antigen-specific IFN-γ production were negligible and not different from controls. (Naseer et al, 2025)
• Challenge Protocol: The study evaluated immunologic responses and protection against experimental challenge in goats vaccinated with LPS combined with ISA 61 VG adjuvant. (Naseer et al, 2025)
• Efficacy: Vaccination with LPS + ISA 61 VG did not confer protection against abortion, uterine, fetal, mammary, or maternal infection compared to controls. (Naseer et al, 2025)
• Description: Vaccination of goats followed by measurement of antibody responses, lymphocyte proliferative responses, T cell proliferation, IFN-γ production, and protection against abortion and infection. (Naseer et al, 2025)